Navigation Links
Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
Date:2/11/2008

lso commonly referred to as biosimilars or biogenerics, in the U.S.

"Dr. Shapiro's comprehensive analysis presents a compelling case for the need for Congress to adopt legislation so patients can receive affordable access to life-saving biotech drugs in a timely manner," said Geoffrey Allan, CEO of Insmed, a developer of follow-on biologics and biopharmaceuticals. "The cost savings to the health care system have the potential to be enormous, while the environment for new market participants could introduce competition to these monopolistic markets, similar to that seen in the traditional pharmaceutical generics industry."

The release of Dr. Shapiro's report is part of Insmed's broad education campaign on the importance of establishing a regulatory pathway in the U.S. for large molecule protein-based drugs, known as follow-on biologics (FOBs), which are also commonly referred to as biosimilars or biogenerics.

Insmed is currently developing a portfolio of FOBs and intends to initiate clinical trials for its first two FOBs in 2008. Members of Insmed's skilled biologics team have worked on over 50 therapeutic proteins. Their focused protein-based drug development backgrounds, coupled with the Company's FDA- approved protein manufacturing facility, and clinical and regulatory expertise, positions Insmed, upon the establishment of a regulatory pathway, to be an initial entrant into the U.S. FOBs market with a broad range of medicines following the expiration of patents covering the innovator products.

Dr. Shapiro is the chairman of Sonecon, LLC, a private firm that advises U.S. and foreign businesses, governments and non-profit organization.

His full report is available on Insmed's website at: http://www.insmed.com. Journalists may contact Dr. Shapiro by calling 202-213-7233 or e-mailing jprocter@gibraltar-llc.com.

Insmed is currently developing a portfolio of FOBs and intends to i
'/>"/>

SOURCE Insmed Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Pittsburgh, PA (PRWEB) January 15, 2014 The ... Company, publisher of Food Safety Tech , an e-Journal ... has signed an agreement for the second year for the ... with Pittcon 2014. The partnership provides that the registration fee ...
(Date:1/15/2014)... Westlake Village, Calif. (PRWEB) January 15, 2014 ... cancer treatment and management through the genomic analysis of ... will offer Therapy Finder™, a web-based cancer decision support ... a reporting option with Cynvenio’s ClearID™ genomic test, Therapy ...
(Date:1/15/2014)... Canada (PRWEB) January 15, 2014 This ... on nonclinical and clinical safety assessment in biosimilars. , ... path for biosimilar drug development, however the complex nature ... to quality, safety and efficacy extremely challenging. Based on ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
Breaking Biology Technology:Pittcon Announces Second Year Partnership With Food Safety Tech 2Pittcon Announces Second Year Partnership With Food Safety Tech 3Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 2Cynvenio Offers New Breast Cancer Therapy Finder Application for its ClearID Breast Cancer Genomic Test 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5
... a regulatory framework to guide the approval of the ... providing more affordable treatment for millions of Americans suffering ... chairman and CEO of Medco Health Solutions, Inc. (NYSE: ... and innovation over a period of many years has ...
... CASTLE, Del., March 12 -- Arkion(R) Life Sciences has ... AV-1011 Liquid Rice Seed Treatment in Louisiana and Missouri ... The EPA approval means that rice growers in these ... grackles. The new bird repellent effectively stops birds ...
... States, long the beneficiary of talented immigrants, must act ... pursue expanding opportunities in their home countries, according to ... Science and Technology .In A Reverse Brain Drain ... Harvard Law School, writes that immigrant scientists and engineers, ...
Cached Biology Technology:Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 2Biogenerics Legislation Provides Critical Pathway to Affordable Access for Patients with Chronic and Complex Conditions 3AV-1011 Bird Repellent to Protect Rice Seed Approved for Use in Louisiana and Missouri 2U.S. Risks Losing Highly Skilled Immigrants 2U.S. Risks Losing Highly Skilled Immigrants 3
(Date:4/23/2014)... announced Sophie Martin of the University of Lausanne, Switzerland, ... The award acknowledges her work to understand the molecular ... cell. , Martin has been working for the past ... way in which the spatial organization of cells contributes ... 11 years, she has been using fission yeast, which ...
(Date:4/23/2014)... new study by a University of Exeter researcher has ... of wild camels thriving in Australia,s remote outback have ... scale. , Sarah Crowley, of the Environment and Sustainability ... the history of the camel in Australia, from their ... to their current status as unwelcome "invader." , The ...
(Date:4/23/2014)... a technique used to read quickly. It involves ... non-essential words and/ or sentences. Similarly to humans, ... quickly "read" genetic information. Genes that need to ... smaller the encoding message, the easier it will ... Instituto Gulbenkian de Cincia (IGC, Portugal) and Centre ...
Breaking Biology News(10 mins):EMBO Gold Medal 2014 awarded to Sophie Martin 2How Australia got the hump with 1 million feral camels 2How Australia got the hump with 1 million feral camels 3Cell division speed influences gene architecture 2
... from North Carolina State University, the University of Washington ... most diverse collections of prehistoric non-native animal remains in ... find contributes to our understanding of culture in the ... may have been more important than previously thought. ...
... The Saint Louis Zoo,s Ron Goellner Center for ... on Nov. 30, 2011, that Ozark hellbenders have been ... subspecies of hellbender. This decade-long collaboration has yielded ... Nov. 15, and currently there are approximately 120 additional ...
... COPENHAGEN, DENMARK/ROCKVILLE, MD, USA Statens Serum Institut and Aeras ... trial of a new candidate TB vaccine designed to protect ... The trial is being conducted by the South African ... in the Western Cape province of South Africa. Dr. Hassan ...
Cached Biology News:Archaeologists find new evidence of animals being introduced to prehistoric Caribbean 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 2World's first captive breeding of Ozark hellbenders at Saint Louis Zoo 3Vaccine targeting latent TB enters clinical testing 2
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation of endotoxins for research purposes. sensitivity 0.05-0.1 EU/mL...
... The Label IT siRNA Tracker Intracellular Localization ... directly label and deliver siRNA, of your ... for in vitro tracking experiments. Subcellular localization ... can be monitored following introduction of the ...
... MW: 60kDa (A) and 36kDa (C) ... pH 7.5, 500mM NaCl, 60mM 2-mercaptoethanol, ... 1mM DTT, and 0.1mg/ml serum albumin ... of proteins. Purification: DEAE chromatography, aminohexyl-agarose ...
... The Label IT siRNA Tracker Intracellular ... to directly label and deliver siRNA, of ... manner, for in vitro tracking experiments. Subcellular ... expression can be monitored following introduction of ...
Biology Products: